Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference17 articles.
1. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial;Lancet,2003
2. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J. Clin. Oncol.,2001
3. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin and paclitaxel;Bookman;J. Clin. Oncol.,1998
4. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J. Clin. Oncol.,1997
5. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinomas: a Gynecologic Oncology Group study;Rose;J. Clin. Oncol.,1998
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. DRG Explant Model: Elucidating Mechanisms of Oxaliplatin-Induced Peripheral Neuropathy and Identifying Potential Therapeutic Targets;2023-10-08
2. Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer;Therapeutic Advances in Medical Oncology;2023-01
3. Platinum vs non-platinum chemotherapy for platinum-resistant ovarian cancer: a systematic review and meta-analysis;2022-07-15
4. Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin αII-Overexpressing Ovarian Carcinoma;Anticancer Research;2020-05
5. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up;Cancer Chemotherapy and Pharmacology;2020-02-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3